March 9, 2021

OICR-affiliated researchers awarded $6.6 million in funding from CIHR

From top-left: Drs. Courtney Jones, Faiyaz Notta, Rima Al-Awar, Trevor Pugh, Naoto Hirano, Hartland Jackson and Kieran Campbell.

The funding will support projects ranging from drug discovery to cancer stem cells

Seven OICR-affiliated researchers have been awarded $6.6 million in funding from the Canadian Institutes for Health Research (CIHR) through its Project Grants program, which is designed to capture ideas with the greatest potential to advance health and research. The funded projects will help support key OICR research in drug discovery, pancreatic cancer, immunotherapy, genomics and circulating tumour DNA, and cancer stem cells.

Dr. Rima Al-Awar
Head, Therapeutic Innovation and Drug Discovery, OICR
The Discovery and Optimization of NUAK Inhibitors: A Novel Approach to Target Hippo Pathway Driven Cancers

Dr. Kieran Campbell
OICR Affiliate, Scientist & Principal Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Characterizing immune evasion in pancreatic adenocarcinoma: an integrative computational and experimental approach to understanding aberrant antigen presentation

Dr. Naoto Hirano
OICR Clinician Scientist, Senior Scientist, Princess Margaret Cancer Centre
Development of TCR-engineered T cells against novel NY-ESO-1 epitopes for the treatment of triple negative breast cancer

Dr. Hartland Jackson
OICR Investigator, Investigator, Lunenfeld-Tanenbaum Research Institute, Sinai Health
Targeting chemotherapy resistant multi-cellular environments in pancreatic cancer

Dr. Courtney Jones
OICR Investigator, Senior Scientist, Princess Margaret Cancer Centre
Characterization and Targeting of SIRT3 in Acute Myeloid Leukemia Stem Cells

Dr. Faiyaz Notta
OICR Associate, Co-Lead, OICR PanCuRx Translational Research Initiative, Scientist, Princess Margaret Cancer Centre
Impact of copy number imbalances in mutant KRAS on pancreatic cancer chemoresistance and metastases

Dr. Trevor Pugh
Senior Investigator and Director, Genomics, OICR
Understanding inevitable relapse of multiple myeloma following highly-effective anti-BCMA treatment

January 13, 2020

Unique Toronto-based clinical trial reveals new subtypes of advanced pancreatic cancer

Drs. Faiyaz Notta and Steven Gallinger, Co-Leaders of OICR’s Pancreatic Cancer Translational Research Initiative (PanCuRx).

Researchers identify five subtypes of pancreatic cancer, uncovering new opportunities for targeted treatment of the aggressive disease

Toronto – (January 13, 2020) Researchers at the Ontario Institute for Cancer Research (OICR) and the University Health Network (UHN) have discovered detailed new information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease.

The study, published today in Nature Genetics, represents the most comprehensive analysis of the molecular subtypes of pancreatic cancer to date. Through detailed genomic and transcriptomic analyses, the research group identified five distinct subtypes of the disease (Basal-like-A, Basal-like-B, Classical-A, Classical-B, and Hybrid) with unique molecular properties that could be targeted with novel chemotherapies, biologics and immunotherapies.

“Therapy development for pancreatic cancer has been hindered by an incomplete knowledge of the molecular subtypes of this deadly disease,” says lead author Dr. Faiyaz Notta, Co-Leader of OICR’s Pancreatic Cancer Translational Research Initiative (PanCuRx) and Scientist at UHN’s Princess Margaret Cancer Centre. “By rigorously analyzing advanced pancreatic cancers – which is the stage of disease that most patients have when they’re diagnosed – we were able to create a framework. This will help us develop better predictive models of disease progression that can assist in personalizing treatment decisions and lead to new targeted therapies.”

The study is based on data from more than 300 patients with both early stage and advanced pancreatic cancer who participated in COMPASS, a first-of-its-kind clinical trial that is breaking new ground in discovery science and personalized pancreatic cancer treatment. COMPASS is enabled by advanced pathology laboratory techniques at UHN and OICR, and next generation sequencing at OICR.

“Most pancreatic cancer research is focused solely on early stage – or resectable – tumours, but in reality, pancreatic cancer is often found in patients after it has advanced and spread to other organs,” says Notta. “COMPASS allowed us to look into these advanced cancers while treating these patients, develop a better understanding of the biology behind metastatic pancreatic cancer, and shed light on the mechanisms driving disease progression.”

Interestingly, the Basal-like-A subtype, which had been difficult to observe before this study, was linked with a specific genetic abnormality. Most of the Basal-like-A tumours harboured several copies of a mutated KRAS gene, also known as a genetic amplification of mutant KRAS. The research group hypothesizes that some of the subtypes arise from specific genetic changes that occur as pancreatic cancer develops.

“This research opens new doors for therapeutic development,” says Dr. Steven Gallinger, Co-Leader of OICR’s PanCuRx, Surgical Oncologist at UHN and Senior Investigator, Lunenfeld Tanenbaum Research Institute at Mount Sinai Hospital. “We look forward to capitalizing on the promise of these discoveries, building on our understanding of pancreatic cancer subtypes, and bringing new treatments to patients with the disease.”

This research was supported by OICR through funding provided by the Government of Ontario, and by the Wallace McCain Centre for Pancreatic Cancer by the Princess Margaret Cancer Foundation, the Terry Fox Research Institute, the Canadian Cancer Society Research Institute, the Pancreatic Cancer Canada Foundation, the Canadian Friends of the Hebrew University and the Cancer Research Society (no. 23383).

October 12, 2016

New findings challenge current view of how pancreas cancer develops

Dr. Faiyaz Notta and Dr. Steven Gallinger

The findings provide important insights into how pancreas cancer develops and spreads and new strategies for better understanding one of the mostly deadly types of cancer.

Toronto (October 12, 2016) – Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network’s Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, today published new findings that challenge current beliefs about how and why pancreas cancer is so aggressive.

Continue reading – New findings challenge current view of how pancreas cancer develops